Please use this identifier to cite or link to this item:
Title: The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study.
Authors: Steward, WP
Middleton, M
Benghiat, A
Loadman, PM
Hayward, C
Waller, S
Ford, S
Halbert, G
Patterson, LH
Talbot, D
First Published: Jun-2007
Citation: ANN ONCOL, 2007, 18 (6), pp. 1098-1103
Abstract: AQ4N (1,4-bis[[2-(dimethylamino)ethyl] amino]-5,8-dihydroxyanthracene-9, 10-dione bis-N-oxide dihydrochloride) is a prodrug which is selectively activated within hypoxic tissues to AQ4, a topoisomerase II inhibitor and DNA intercalator.
DOI Link: 10.1093/annonc/mdm120
ISSN: 0923-7534
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.